Related Experiment Video

Updated: Sep 25, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Growth hormone treatment in a girl with Prader Willi syndrome

S N Pandey1, R A Vaidya, A Irani

  • 1Bhavan's SPARC Center for Disorders of Growth & Puberty 13th N.S. Road, JVPD, Mumbai-400 049. bhaspa@bom5.vsnl.net.in

Indian Journal of Pediatrics
|June 10, 2003
PubMed

Insights

Prader Willi syndrome (PWS) patients may benefit from growth hormone (GH) therapy. This treatment improved linear growth and metabolic function, with some lasting effects after discontinuation.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Genetics

Background:

  • Prader Willi syndrome (PWS) is a rare genetic disorder affecting multiple endocrine and metabolic functions.
  • Key features include hypotonia, hyperphagia, obesity, short stature, hypogonadism, and behavioral issues.
  • A significant percentage of individuals with PWS develop diabetes mellitus and often exhibit growth hormone (GH) deficiency.

Observation:

  • Growth hormone (GH) replacement therapy has shown promise in addressing PWS characteristics.
  • Recent research suggests GH therapy benefits linear growth and metabolic dysfunctions.
  • This case study examines the therapeutic outcome in a girl with PWS treated with recombinant GH (rGH).

Findings:

  • Treatment with recombinant growth hormone (rGH), specifically Genotropin, was administered to a girl with PWS.
  • The therapy demonstrated positive effects on the patient's condition.
  • Notably, some therapeutic benefits persisted even after the cessation of rGH treatment.

Implications:

  • Growth hormone replacement therapy may be a valuable therapeutic option for managing PWS.
  • Further research into the long-term effects and optimal use of GH in PWS is warranted.
  • Understanding carry-over benefits could inform treatment strategies and improve patient outcomes.

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
What is Genetic Engineering?01:34

What is Genetic Engineering?

Genetic engineering is the process of modifying an organism’s DNA to introduce new, desirable traits. Many organisms, from bacteria to plants and animals, have been genetically modified for academic, medical, agricultural, and industrial purposes. While genetic engineering has definite benefits, ethical concerns surround modifying humans and our food supply.Scientists can Deliberately Modify an Organism’s GenomeGenetic engineering is possible because the genetic code—the way information is...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...